Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-31 10:09 am Sale | 2024-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | The Vanguard Group | 8,200,903 4.800% | -239,827 (-2.84%) | Filing History |
| 2024-11-12 5:59 pm Unchanged | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | The Vanguard Group | 8,440,730 5.000% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 11,210,671 6.700% | 0 (Unchanged) | Filing History |
| 2024-11-04 2:15 pm Purchase | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | The Vanguard Group | 8,440,730 5.000% | 8,440,730 (New Position) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 11,210,671 6.700% | 3,049,924 (+37.37%) | Filing History |
| 2024-02-14 7:36 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 11,494,437 6.700% | 1,165,788 (+11.29%) | Filing History |
| 2024-02-14 4:44 pm Purchase | 2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | ACORN BIOVENTURES, L.P. | 17,755,869 9.990% | 17,755,869 (New Position) | Filing History |
| 2024-02-14 4:32 pm Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Lincoln Park Capital Fund LLC | 1,600,136 0.947% | -209,951 (-11.60%) | Filing History |
| 2024-02-13 6:55 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund L.P. | 16,915,784 11.000% | 4,713,274 (+38.63%) | Filing History |
| 2024-02-07 5:09 pm Sale | 2024-01-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 8,160,747 4.900% | -256,777 (-3.05%) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 8,417,524 5.000% | 7,343,033 (+683.40%) | Filing History |
| 2024-01-16 4:18 pm Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Millennium Management LLC | 1,664,317 1.000% | -6,604,499 (-79.87%) | Filing History |
| 2024-01-08 10:26 am Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Empery Asset Management LP | 4,549,605 2.650% | -1,649,079 (-26.60%) | Filing History |
| 2023-06-16 4:04 pm Purchase | 2023-06-09 | 13G | X4 Pharmaceuticals, Inc. XFOR | Millennium Management LLC | 8,268,816 5.200% | 8,268,816 (New Position) | Filing History |
| 2023-05-26 3:03 pm Purchase | 2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE LLC | 15,742,792 9.990% | 3,605,999 (+29.71%) | Filing History |
| 2023-02-14 5:24 pm Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 10,328,649 8.200% | 8,492,300 (+462.46%) | Filing History |
| 2023-02-14 4:18 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management L.P. | 913,242 1.300% | -719,962 (-44.08%) | Filing History |
| 2023-02-14 11:26 am Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital LLC | 349,133 0.300% | -1,915,358 (-84.58%) | Filing History |
| 2023-02-14 06:34 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund L.P. | 12,202,510 11.000% | 9,315,968 (+322.74%) | Filing History |
| 2023-02-13 5:51 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 2,258,400 1.900% | -769,272 (-25.41%) | Filing History |